GlassScriptPhysician profile
Thomas R Conklin
NPI 1376542555
$1,265.52
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $592 · 2020: $154 · 2021: $311 · 2022: $208.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $304.27 | 2019-2021 | |
| Aerie Pharmaceuticals, INC. | $220.34 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $205.03 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $147.63 | 2021-2022 | |
| Sight Sciences, INC. | $132.59 | 2019-2020 | |
| Hoffmann-La Roche Limited | $99.00 | 2019 | |
| Abbvie INC. | $44.32 | 2022 | |
| Dompe US, INC. | $34.15 | 2021-2022 | |
| Biotissue Holdings INC. | $24.90 | 2020 | |
| Rayner Intraocular Lenses Limited | $19.84 | 2022 | |
| Alcon Vision LLC | $17.55 | 2022 | |
| Johnson & Johnson Surgical Vision, INC. | $15.90 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Conklin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.